Skip to main content

Table 1 Baseline Characteristics and Outcomes

From: N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia

Variable IPF Cohort (n = 216) IPAF-UIP Cohort (n = 77) Combined UIP Cohort (n = 293)a
Age, mean (±SD) 69.3 (7.8) 63.3 (9.9) 67.7 (8.8)
Male Gender, n (%) 160 (74.1) 41 (53.3) 201 (68.6)
Race, n (%)
 White 182 (84.3) 59 (76.6) 241 (82.3)
 African American 15 (6.9) 9 (11.7) 24 (8.2)
 Hispanic 10 (4.6) 8 (10.4) 18 (6.1)
 Asian 9 (4.2) 1 (1.3) 10 (3.4)
Any auto-antibody (+) 93 (43.1) 74 (96.1) 167 (57.0)
ANA (+) b 84 (38.9) 64 (83.1) 148 (50.5)
HRCT, n (%)
 UIP 156 (72.2) 41 (54) 197 (67.5)
 Possible UIP 36 (16.7) 14 (18.4) 50 (17.1)
 Inconsistent with UIP 24 (11.1) 21 (27.6) 45 (15.4)
UIP by SLB c, n (%) 93 (97.9) 55 (100) 148 (98.7)
FVC (% pred), mean (±SD) 67.5 (17.4) 63.5 (16.9) 66.5 (17.4)
DLCO (% pred), mean (±SD) 51.1 (17.1) 48.1 (16.8) 50.3 (17.1)
GAP Score, mean (±SD) 4.1 (1.6) 3.7 (1.6) 4.0 (1.6)
Outcomes
 Death 108 (50) 35 (45.5) 143 (48.8)
 Transplant 14 (6.5) 14 (18.2) 28 (9.6)
  1. Abbreviations: IPF idiopathic pulmonary fibrosis, IPAF interstitial pneumonia with autoimmune features, ANA anti-nuclear antibody, HRCT high-resolution computed tomography, UIP usual interstitial pneumonia, SLB surgical lung biopsy, FVC forced vital capacity, DLCO diffusion capacity of the lung for carbon monoxide, GAP gender, age, physiology
  2. aException for n: Other auto-antibody (n = 88); HRCT (n = 292); UIP by SLB (n = 150); DLCO (n = 272)
  3. bANA titer ≥1:320 or nucleolar or centromere staining pattern at any titer
  4. cTwo patients without UIP by SLB were deemed to have IPF due to family history of pulmonary fibrosis